12:00 AM
 | 
Apr 27, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Vivitrol naltrexone: Phase IIIb start

This quarter, Alkermes will begin an open-label Phase IIIb trial (ALK21-021) to evaluate 380 mg of intramuscular Vivitrol given once monthly in combination with psychosocial support for 24 months in about...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >